X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (28) 28
humans (24) 24
female (23) 23
breast cancer (20) 20
article (19) 19
breast neoplasms - drug therapy (16) 16
oncology (15) 15
breast neoplasms - genetics (14) 14
animals (11) 11
breast neoplasms - pathology (11) 11
mice (10) 10
breast neoplasms - metabolism (9) 9
mutation (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
cancer (7) 7
cell biology (7) 7
chemotherapy (7) 7
endocrine therapy (7) 7
estrogen (7) 7
phosphorylation (7) 7
research (7) 7
tamoxifen (7) 7
tumors (7) 7
anastrozole (6) 6
apoptosis (6) 6
breast neoplasms - chemistry (6) 6
cell proliferation (6) 6
expression (6) 6
health aspects (6) 6
mutations (6) 6
neoplasm staging (6) 6
receptors, estrogen - analysis (6) 6
receptors, estrogen - metabolism (6) 6
treatment outcome (6) 6
aged (5) 5
antineoplastic agents - therapeutic use (5) 5
aromatase inhibitors - therapeutic use (5) 5
breast (5) 5
cell cycle (5) 5
gene amplification (5) 5
genetic aspects (5) 5
middle aged (5) 5
multidisciplinary sciences (5) 5
pathway (5) 5
prognosis (5) 5
xenograft model antitumor assays (5) 5
adult (4) 4
apoptosis - drug effects (4) 4
biomarkers (4) 4
cell line, tumor (4) 4
cell proliferation - drug effects (4) 4
càncer de mama (4) 4
erbb-2 protein (4) 4
fulvestrant (4) 4
gene expression regulation, neoplastic (4) 4
genetics & heredity (4) 4
genomics (4) 4
improved surgical outcomes (4) 4
inhibitors (4) 4
ki-67 antigen - analysis (4) 4
letrozole (4) 4
lung-cancer (4) 4
metastasis (4) 4
neoadjuvant therapy (4) 4
nitriles - therapeutic use (4) 4
palbociclib (4) 4
proliferation (4) 4
protein kinase inhibitors - pharmacology (4) 4
triazoles - therapeutic use (4) 4
activation (3) 3
androstadienes - therapeutic use (3) 3
antineoplastic agents - pharmacology (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
aromatase inhibitor (3) 3
biology (3) 3
breast neoplasms - diagnosis (3) 3
cancer therapies (3) 3
cdk4 (3) 3
cyclin-dependent kinase 4 (3) 3
discovery (3) 3
estrogen receptor (3) 3
estrogen receptor alpha - genetics (3) 3
estrogen receptors (3) 3
estrògens (3) 3
gene expression (3) 3
gene expression profiling (3) 3
gene mutations (3) 3
genetics (3) 3
genomes (3) 3
hormone receptors (3) 3
inhibition (3) 3
kaplan-meier estimate (3) 3
kinases (3) 3
mechanisms (3) 3
medical research (3) 3
medicine, research & experimental (3) 3
mice, inbred nod (3) 3
mice, scid (3) 3
molecular targeted therapy (3) 3
mutation - genetics (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature, ISSN 0028-0836, 08/2017, Volume 548, Issue 7668, pp. 471 - 475
Cyclin-dependent kinases 4 and 6 (CDK4/6) are fundamental drivers of the cell cycle and are required for the initiation and progression of various... 
BREAST-CANCER | CELLS | METHYLATION | MULTIDISCIPLINARY SCIENCES | SENESCENCE | EXPRESSION | REQUIREMENT | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Viruses - genetics | Breast Neoplasms - immunology | Humans | Transcriptome | T-Lymphocytes, Regulatory - immunology | T-Lymphocytes, Regulatory - cytology | Female | Biological Mimicry - drug effects | Phosphorylation - drug effects | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Disease Models, Animal | Viruses - drug effects | Viruses - immunology | Antigen Presentation - immunology | Breast Neoplasms - drug therapy | T-Lymphocytes, Regulatory - drug effects | Animals | Breast Neoplasms - genetics | Repressor Proteins - biosynthesis | Signal Transduction - drug effects | Breast Neoplasms - pathology | Cell Cycle Checkpoints - drug effects | Protein Kinase Inhibitors - therapeutic use | RNA, Double-Stranded - genetics | Cell Line, Tumor | Interferons - metabolism | Antigen Presentation - drug effects | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Oncology, Experimental | Cancer cells | Physiological aspects | Research | Protein kinases | Immunity | Cyclins | Cancer | Cell proliferation | Flow cytometry | Animal models | Phosphorylation | Senescence | Peptides | Genomics | Immune clearance | Cytotoxicity | Lymphocytes T | Genomes | Kinases | Cancer therapies | Cyclin-dependent kinase 4 | E2F protein | Breast carcinoma | Cell growth | Lymphocytes | New combinations | Cell cycle | Inhibition | Deoxyribonucleic acid--DNA | Immune system | Antigen presentation | Medical research | Immune response | Immunoregulation | Intracellular levels | Double-stranded RNA | Breast cancer | Pharmacology | Gene expression | Ribonucleic acid--RNA | Inhibitors | Immune checkpoint | Immunogenicity | Breast | DNA methyltransferase | Interferon | Retinoblastoma | Tumors | Apoptosis
Journal Article
Nature, ISSN 0028-0836, 06/2012, Volume 486, Issue 7403, pp. 353 - 360
Journal Article
Journal Article
Nature, ISSN 0028-0836, 04/2010, Volume 464, Issue 7291, pp. 999 - 1005
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4055 - 4065
Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor-positive (ER+) breast cancer. This single-arm phase II neoadjuvant... 
TRIAL | AROMATASE INHIBITOR | 1ST-LINE TREATMENT | RETINOBLASTOMA PROTEIN | ONCOLOGY | INTRINSIC SUBTYPE | IN-VIVO | DOUBLE-BLIND | LETROZOLE | CELL-PROLIFERATION | POSTMENOPAUSAL WOMEN | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Breast Neoplasms - surgery | Triazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Class I Phosphatidylinositol 3-Kinases - genetics | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Nitriles - administration & dosage | Pyridines - adverse effects | Adult | Female | Neoadjuvant Therapy | Gene Expression Regulation, Neoplastic - drug effects | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Pyridines - administration & dosage | Breast Neoplasms - drug therapy | Piperazines - adverse effects | Disease-Free Survival | Breast Neoplasms - genetics | Estrogen Receptor alpha - genetics | Breast Neoplasms - pathology | Aged | Cell Proliferation - drug effects | Mutation | Neoplasm Staging | Cell proliferation | Anastrozole | Estrogens | Cyclin-dependent kinases | Estrogen | Estrogen receptors | Breast cancer | Kinases | Gene expression | Patients | ErbB-2 protein | Cyclin-dependent kinase 4 | Cyclin-dependent kinase | E2F protein | Inhibitors | Experimental design | Surgery | Cell cycle | Breast | Cancer | breast cancer | neoadjuvant | anastrozole | CDK4 | palbociclib
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 04/2012, Volume 122, Issue 4, pp. 1541 - 1552
Patients with triple-negative breast cancer (TNBC) - defined by lack of estrogen receptor and progesterone receptor expression as well as lack of human... 
SURVIVAL | MEDICINE, RESEARCH & EXPERIMENTAL | P53 MUTATION | CHECKPOINT KINASE-1 | PATHWAY | PROTEIN-KINASE | 7-HYDROXYSTAUROSPORINE UCN-01 | DNA-DAMAGE | S-PHASE | PREDICTIVE-VALUE | CDC25A PHOSPHATASE | Thiophenes - therapeutic use | Apoptosis - drug effects | Humans | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Receptors, Progesterone - genetics | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Camptothecin - administration & dosage | Antineoplastic Agents, Phytogenic - therapeutic use | Camptothecin - analogs & derivatives | Thiophenes - pharmacology | Tumor Suppressor Protein p53 - deficiency | Breast Neoplasms - drug therapy | DNA, Neoplasm - drug effects | Protein Kinase Inhibitors - administration & dosage | Urea - therapeutic use | Mice, Inbred NOD | Mice | DNA Damage | Cell Cycle - drug effects | Genes, cdc | Staurosporine - pharmacology | Urea - pharmacology | Staurosporine - administration & dosage | Neoplasm Proteins - physiology | Staurosporine - analogs & derivatives | Cell Line, Tumor - transplantation | Receptors, Estrogen - analysis | Thiophenes - administration & dosage | Molecular Targeted Therapy | Genes, p53 | Urea - analogs & derivatives | Female | Antineoplastic Agents - pharmacology | Cell Line, Tumor - metabolism | Urea - administration & dosage | Protein Kinases - drug effects | Receptors, Estrogen - genetics | Camptothecin - therapeutic use | Mice, SCID | Xenograft Model Antitumor Assays | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Genes, erbB-2 | Protein Kinase Inhibitors - therapeutic use | Staurosporine - therapeutic use | Protein Kinases - physiology | Checkpoint Kinase 1 | Neoplasm Proteins - analysis | Protein Kinase Inhibitors - pharmacology | Breast cancer | Genetic aspects | Research | Gene mutations | Health aspects | DNA damage | Estrogen | Càncer de mama | Ratolins (Animals de laboratori) | Apoptosi | Receptors d'hormones | Hormone receptors | Chemotherapy | Mice (Laboratory animals) | Progesterone | Quimioteràpia | Progesterona | Estrògens | Apoptosis
Journal Article
Cell Reports, ISSN 2211-1247, 09/2013, Volume 4, Issue 6, pp. 1116 - 1130
Journal Article
Nature Communications, ISSN 2041-1723, 08/2016, Volume 7, Issue 1, p. 12498
Resistance to oestrogen-deprivation therapy is common in oestrogen-receptor- positive (ER + ) breast cancer. To better understand the contributions of tumour... 
HETEROGENEITY | LUNG-CANCER | IMPROVED SURGICAL OUTCOMES | PHASE-II TRIAL | WHOLE-GENOME | EVOLUTION | MULTIDISCIPLINARY SCIENCES | ENDOCRINE-THERAPY | RESISTANCE | ACUTE MYELOID-LEUKEMIA | MUTATIONS
Journal Article
Journal Article